DUBLIN–(BUSINESS WIRE)–The “Friedreich Ataxia – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Friedreich Ataxia – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Friedreich Ataxia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Friedreich Ataxia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 4, 17, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.
Friedreich Ataxia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Friedreich Ataxia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Friedreich Ataxia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. (Read more…)
- The pipeline guide reviews key companies involved in Friedreich Ataxia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Friedreich Ataxia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Friedreich Ataxia (Central Nervous System)
Key Topics Covered:
Introduction
Friedreich Ataxia – Overview
Friedreich Ataxia – Therapeutics Development
Friedreich Ataxia – Therapeutics Assessment
Friedreich Ataxia – Companies Involved in Therapeutics Development
Friedreich Ataxia – Drug Profiles
Friedreich Ataxia – Dormant Projects
Friedreich Ataxia – Discontinued Products
Friedreich Ataxia – Product Development Milestones
Appendix
Companies Mentioned
- AavantiBio Inc
- Adverum Biotechnologies Inc
- Amylyx Pharmaceutical Corp
- Anima Biotech Inc
- Biointaxis SL
- BioMarin Pharmaceutical Inc
- Biovista Inc
- CRISPR Therapeutics AG
- Design Therapeutics Inc
- Epirium Bio Inc
- Exicure Inc
- Fratagene Therapeutics Srl
- Fulcrum Therapeutics Inc
- Ixchel Pharma LLC
- Jupiter Orphan Therapeutics Inc
- Lacerta Therapeutics Inc
- Larimar Therapeutics Inc
- Metro International Biotech LLC
- Minoryx Therapeutics sl
- Novartis Gene Therapies
- PTC Therapeutics Inc
- Reata Pharmaceuticals Inc
- Retrotope Inc
- Seelos Therapeutics, Inc.
- STATegics Inc
- Stealth BioTherapeutics Corp
- StrideBio Inc
- Voyager Therapeutics Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/uncasl
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900